- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.60 Å
- Oligo State
- homo-trimer
- Ligands
- 3 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x CL: CHLORIDE ION(Non-functional Binders)
- 18 x SO4: SULFATE ION(Non-functional Binders)
SO4.3: 5 residues within 4Å:- Chain A: S.443, K.445, G.464, K.465, S.466
Ligand excluded by PLIPSO4.4: 4 residues within 4Å:- Chain A: V.192, L.193, D.194, K.226
Ligand excluded by PLIPSO4.5: 4 residues within 4Å:- Chain A: L.273, N.276, N.277, R.364
Ligand excluded by PLIPSO4.6: 4 residues within 4Å:- Chain A: N.444, K.445, G.446, K.461
Ligand excluded by PLIPSO4.7: 2 residues within 4Å:- Chain A: G.471, E.472
Ligand excluded by PLIPSO4.8: 5 residues within 4Å:- Chain A: K.498
- Chain B: K.498
- Chain C: K.498
- Ligands: SO4.18, SO4.28
Ligand excluded by PLIPSO4.13: 5 residues within 4Å:- Chain B: S.443, K.445, G.464, K.465, S.466
Ligand excluded by PLIPSO4.14: 4 residues within 4Å:- Chain B: V.192, L.193, D.194, K.226
Ligand excluded by PLIPSO4.15: 4 residues within 4Å:- Chain B: L.273, N.276, N.277, R.364
Ligand excluded by PLIPSO4.16: 4 residues within 4Å:- Chain B: N.444, K.445, G.446, K.461
Ligand excluded by PLIPSO4.17: 2 residues within 4Å:- Chain B: G.471, E.472
Ligand excluded by PLIPSO4.18: 5 residues within 4Å:- Chain A: K.498
- Chain B: K.498
- Chain C: K.498
- Ligands: SO4.8, SO4.28
Ligand excluded by PLIPSO4.23: 5 residues within 4Å:- Chain C: S.443, K.445, G.464, K.465, S.466
Ligand excluded by PLIPSO4.24: 4 residues within 4Å:- Chain C: V.192, L.193, D.194, K.226
Ligand excluded by PLIPSO4.25: 4 residues within 4Å:- Chain C: L.273, N.276, N.277, R.364
Ligand excluded by PLIPSO4.26: 4 residues within 4Å:- Chain C: N.444, K.445, G.446, K.461
Ligand excluded by PLIPSO4.27: 2 residues within 4Å:- Chain C: G.471, E.472
Ligand excluded by PLIPSO4.28: 5 residues within 4Å:- Chain A: K.498
- Chain B: K.498
- Chain C: K.498
- Ligands: SO4.8, SO4.18
Ligand excluded by PLIP- 3 x R0J: 3-{[5-chloro-1-(4,4,4-trifluorobutyl)-1H-imidazo[4,5-b]pyridin-2-yl]methyl}-1-cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one(Non-covalent)
R0J.9: 16 residues within 4Å:- Chain A: F.137, F.140, M.396, T.397, D.486, E.487, F.488
- Chain B: F.137, F.488
- Chain C: F.140, F.488, D.489
- Ligands: TAR.10, R0J.19, TAR.20, R0J.29
13 PLIP interactions:4 interactions with chain B, 5 interactions with chain A, 4 interactions with chain C- Hydrophobic interactions: B:F.137, B:F.488, A:F.140, A:F.488, A:F.488, A:F.488, C:F.140, C:F.140, C:D.489
- pi-Stacking: B:F.488, B:F.488, A:F.140, C:F.488
R0J.19: 16 residues within 4Å:- Chain A: F.140, F.488, D.489
- Chain B: F.137, F.140, M.396, T.397, D.486, E.487, F.488
- Chain C: F.137, F.488
- Ligands: R0J.9, TAR.20, R0J.29, TAR.30
13 PLIP interactions:5 interactions with chain B, 4 interactions with chain A, 4 interactions with chain C- Hydrophobic interactions: B:F.140, B:F.488, B:F.488, B:F.488, A:F.140, A:F.140, A:D.489, C:F.137, C:F.488
- pi-Stacking: B:F.140, A:F.488, C:F.488, C:F.488
R0J.29: 16 residues within 4Å:- Chain A: F.137, F.488
- Chain B: F.140, F.488, D.489
- Chain C: F.137, F.140, M.396, T.397, D.486, E.487, F.488
- Ligands: R0J.9, TAR.10, R0J.19, TAR.30
13 PLIP interactions:4 interactions with chain B, 5 interactions with chain C, 4 interactions with chain A- Hydrophobic interactions: B:F.140, B:F.140, B:D.489, C:F.140, C:F.488, C:F.488, C:F.488, A:F.137, A:F.488
- pi-Stacking: B:F.488, C:F.140, A:F.488, A:F.488
- 3 x TAR: D(-)-TARTARIC ACID(Non-covalent)
TAR.10: 9 residues within 4Å:- Chain A: F.137, L.138, G.139, F.140, P.353, Q.354, E.356
- Ligands: R0J.9, R0J.29
7 PLIP interactions:7 interactions with chain A- Hydrogen bonds: A:F.137, A:F.137, A:F.137, A:F.137, A:G.139, A:F.140, A:Q.354
TAR.20: 9 residues within 4Å:- Chain B: F.137, L.138, G.139, F.140, P.353, Q.354, E.356
- Ligands: R0J.9, R0J.19
7 PLIP interactions:7 interactions with chain B- Hydrogen bonds: B:F.137, B:F.137, B:F.137, B:F.137, B:G.139, B:F.140, B:Q.354
TAR.30: 9 residues within 4Å:- Chain C: F.137, L.138, G.139, F.140, P.353, Q.354, E.356
- Ligands: R0J.19, R0J.29
6 PLIP interactions:6 interactions with chain C- Hydrogen bonds: C:F.137, C:F.137, C:F.137, C:G.139, C:F.140, C:Q.354
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Vendeville, S. et al., Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus. J.Med.Chem. (2020)
- Release Date
- 2020-05-27
- Peptides
- Prefusion RSV F (DS-Cav1),Envelope glycoprotein: ABC
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
FB
FC
F
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.60 Å
- Oligo State
- homo-trimer
- Ligands
- 3 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x CL: CHLORIDE ION(Non-functional Binders)
- 18 x SO4: SULFATE ION(Non-functional Binders)
- 3 x R0J: 3-{[5-chloro-1-(4,4,4-trifluorobutyl)-1H-imidazo[4,5-b]pyridin-2-yl]methyl}-1-cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one(Non-covalent)
- 3 x TAR: D(-)-TARTARIC ACID(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Vendeville, S. et al., Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus. J.Med.Chem. (2020)
- Release Date
- 2020-05-27
- Peptides
- Prefusion RSV F (DS-Cav1),Envelope glycoprotein: ABC
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
FB
FC
F